Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats
Laboratory Animal Research volume 34, pages 80–83 (2018)
The elimination half-lives of in Interleukin-6 (IL-6) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) in rats after inflammatory stimulation were investigated. Five male Sprague-Dawley rats were used (age, 9 weeks; body weight, 235–375 g). Turpentine oil was intramuscularly injected at a dose of 2 mL/kg body weight to induce acute inflammation. Blood was collected pre-injection and 6, 12, 24, 36, 48, 60, 72, 84, and 96 h after the turpentine oil injection. Serum concentrations of IL-6, CINC-1, and α2-macroglobulin (α2M) were measured by enzyme-linked immunosorbent assay. Half-lives were calculated as 0.693/elimination rate constant. The serum concentration of α2M peaked at 48 h after turpentine oil injection. Serum concentrations of IL-6 and CINC-1 increased and peaked at 12 and 24 h, respectively. The terminal elimination half-lives of IL-6 and CINC-1 were 15.5 and 29.9 h, respectively. The half-life of CINC-1 was significantly longer than that of IL-6 (P=0.006). These results suggested that these cytokines synthesized in response to inflammatory stimulation were rapidly eliminated in rats. The serum concentrations of these cytokines should be measured at an early stage if these cytokines will be used as surrogate inflammatory markers instead of acute-phase proteins.
Inoue S, Jinbo T, Shino M, Iguchi K, Nomura M, Kawato K, Yamamoto S. Determination of α2-macroglobulin concentrations in healthy rats of various ages and rats inoculated with turpentine oil by an enzyme-linked immunosorbent assay. J. Exp. Anim. Sci. 2001; 42(1): 44–49.
Jinbo T, Motoki M, Yamamoto S. Variation of serum α2-macroglobulin concentration in healthy rats and rats inoculated with Staphylococcus aureus or subjected to surgery. Comp Med 2001; 51(4): 332–335.
Jinbo T, Sakamoto T, Yamamoto S. Serum α2-macroglobulin and cytokine measurements in an acute inflammation model in rats. Lab Anim 2002; 36(2): 153–157.
Honjo T, Kuribayashi T, Seita T, Mokonuma Y, Yamaga A, Yamazaki S, Yamamoto S. The effects of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 on α2-macroglobulin production in rats. Exp Anim 2010; 59(5): 589–594.
Kuribayashi T, Tomizawa M, Seita T, Tagata K, Yamamoto S. Relationship between production of acute-phase proteins and strength of inflammatory stimulation in rats. Lab Anim 2011; 45(3): 215–218.
Kuribayashi T, Seita T, Kawato K, Yamazaki S, Yamamoto S. Comparison of α2-macroglobulin synthesis by juvenile vs. mature rats after identical inflammatory stimulation. Inflammation 2013; 36(6): 1448–1452.
Honjo T, Kuribayashi T, Matsumoto M, Yamazaki S, Yamamoto S. Kinetics of α2-macroglobulin and α1-acid glycoprotein in rats subjected to repeated acute inflammatory stimulation. Lab Anim 2010; 44(2): 150–154.
Kuribayashi T, Seita T, Honjo T, Yamazaki S, Momotani E, Yamamoto S. Impairment of α2-macroglobulin synthesis in experimental hepatopathic rats treated with turpentine oil. Exp Anim 2012; 61(2): 125–130.
Todd I, Spickett G. Lecture notes Immunology, 6th ed, Wiley-Blackwell, USA, 2011; pp. 42–54.
Weber RL, Iacono VJ. The cytokines: a review of interleukins. Periodontal Clin Investig 1997; 19(1): 17–22.
Whiteside TL. Cytokine assays. Biotechniques 2002; 33: S4–S15.
Prasad VG, Vivek Ch, Anand Kumar P, Ravi Kumar P, Rao GS. Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetion without altering its elimination process in rats. Eur J Drug Metab Pharmacokinet 2015; 40(1): 23–28.
Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. J Am Assoc Lab Anim Sci 2013; 52(5): 567–570.
Rycroft D, Sosabowski J, Coulstock E, Davies M, Morrey J, Friel S, Kelly F, Hamatake R, Oveèka M, Prince R, Goodall L, Sepp A, Walker A. Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha. PLoS One 2015; 10(2): e0117847.
Kuribayashi T, Seita T, Momotani E, Yamazaki S, Hagimori K, Yamamoto S. Elimination half-lives of acute-phase proteins in rats and beagle dogs during acute inflammation. Inflammation 2015; 38(4): 1401–1405.
Hu X, Shang S, Nestorov I, Hasan J, Seddighzadeh A, Dawson K, Sperling B, Werneburg B. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. Br J Clin Pharmacol 2016; 82(2): 380–388.
Grace MJ, Cutler D. Pegylating IFNs at His-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 2004; 15(6): 287–297.
Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010; 70(2): 147–165.
White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M. Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Ther Adv Neurol Disord 2016; 9(4): 239–249.
Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y. Phase I study of pegylated interferon-alpha-2a as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol 2016; 43(10): 1146–1153.
About this article
Cite this article
Kuribayashi, T. Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats. Lab Anim Res 34, 80–83 (2018). https://doi.org/10.5625/lar.2018.34.2.80